O
Ocular Therapeutix, Inc. (OCUL)
NGM – Real vaqt narxi. Valyuta: USD
7.55
-0.52 (-6.44%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
7.51
-0.04 (-0.57%)
Bozordan keyin: Mar 27, 2026, 6:40 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
NGM – Real vaqt narxi. Valyuta: USD
7.55
-0.52 (-6.44%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
7.51
-0.04 (-0.57%)
Bozordan keyin: Mar 27, 2026, 6:40 PM EDT
Ocular Therapeutix, Inc., bioteхnologiya kompaniyasi, AQShda biomobil gidrogel asosidagi formulasi texnologiyasidan foydalangan holda ko'z kasalliklari va boshqa ko'z holatlari uchun terapiya ishlab chiqish va tijoratlashtirish bilan shug'ullanadi. Kompaniya DEXTENZA, oftalmik jarrohlikdan keyingi ko'zning yallig'lanishi va og'rig'ini, shuningdek, allergik kon'yunktivitni davolash uchun deksametazon oftalmik implantini sotadi. Kompaniya, shuningdek, nam yoshga bog'liq makula degeneratsiyasi va proliferativ bo'lmagan diabetik retinopatiyani davolash uchun 3-bosqich klinik sinovlarida bo'lgan akitinib intravitreal gidrogel AXPAXLI; ochiq burchakli glaukoma yoki ko'z gipertenziyasini davolash uchun 2-bosqich klinik sinovlarini tugatgan travoprost intrakameral gidrogel OTX-TICni ishlab chiqmoqda. Kompaniya DEXTENZA va OTX-TICni ishlab chiqish va tijoratlashtirish uchun AffaMed Therapeutics Limited bilan litsenziyalash shartnomasi va hamkorlikka ega. Ocular Therapeutix, Inc. 2006 yilda ro'yxatga olingan va shtab-kvartirasi Bedford, Massachusetsda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Jeffrey S. Heier M.D. | Chief Scientific Officer |
| Dr. Peter K. Jarrett Ph.D. | Chief Technical Officer |
| Dr. Peter K. Kaiser M.D. | Chief Development Officer |
| Dr. Pravin U. Dugel M.D. | Executive Chairman, President & CEO |
| Mr. Barry Rubenstein M.S. | Chief Human Resources Officer |
| Mr. Donald Notman Jr. | CFO, COO & Principal Accounting Officer (Leave of Absence) |
| Mr. Jason Robins | Senior VP of Finance, Interim CFO & Principal Accounting Officer |
| Mr. Todd D.C. Anderman J.D. | Chief Legal Officer & Corporate Secretary |
| Mr. William H. Ransone II | Vice President of Global Sales & Marketing |
| Mr. William S. Slattery Jr. | Vice President of Investor Relations |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-01-23 | 8-K | tm263902d1_8k.htm |
| 2025-12-18 | 8-K | tm2533889d1_8k.htm |
| 2025-12-05 | 8-K | tm2532882d1_8k.htm |
| 2025-11-04 | 10-Q | ocul-20250930x10q.htm |
| 2025-08-05 | 8-K | tm2522503d1_8k.htm |
| 2025-06-11 | 8-K | tm2517563d2_8k.htm |
| 2025-05-05 | 8-K | tm2513949d1_8k.htm |
| 2025-04-29 | DEF 14A | ocul-20250611xdef14a.htm |
| 2025-04-18 | PRE 14A | ocul-20250611xpre14a.htm |
| 2025-03-03 | 8-K | tm258051d1_8k.htm |